T1	Participants 609 626	autistic children
T2	Participants 86 117	children with autistic disorder
T3	Participants 609 660	autistic children who were not optimally responding
T4	Participants 819 1095	male and female outpatients aged 5-12 years with a diagnosis of autistic disorder based on the DSM-IV-TR criteria and a score of ≥12 on the Aberrant Behavior Checklist-Community (ABC-C) irritability subscale who had discontinued other medications because of a lack of efficacy
T5	Participants 1661 1747	Forty-nine patients were enrolled in the study, and forty children completed the trial
T6	Participants 2286 2392	Eleven patients in the riluzole group and five patients in the placebo group were classified as responders
